TABLE 3.
Investigator assessment of clinical success at the posttherapy evaluation visit by baseline pathogen in the microbiological intent-to-treat population
| Speciesa | No. of patients with clinical success/no. of patients with pathogen confirmed at baseline (%) |
|
|---|---|---|
| Tedizolid phosphate (N = 113) | Linezolid (N = 126) | |
| Staphylococcus aureusb | 60/79 (75.9) | 70/95 (73.7) |
| MSSA | 40/51 (78.4) | 51/64 (79.7) |
| MRSA | 21/29 (72.4) | 20/32 (62.5) |
| Streptococcus anginosus | 21/23 (91.3) | 18/23 (78.3) |
| Streptococcus pyogenes | 2/4 (50.0) | 5/6 (83.3) |
| Streptococcus mitis group | 4/4 (100) | 4/4 (100) |
a
Other Gram-positive pathogens in very small numbers included the following: Staphylococcus haemolyticus, Streptococcus canis, Staphylococcus lugdunensis, Streptococcus agalactiae, Enterococcus faecalis, Enterococcus spp., Gemella morbillorum, Mycobacterium fortuitum, Clostridium tertium, Finegoldia magna, and Propionibacterium avidum. MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-susceptible S. aureus.
b
One patient in the tedizolid arm and one patient in the linezolid arm had been infected with both MSSA and MRSA; data are shown by patient.